Special Issue

Neuromuscular and Neurodegenerative Diseases: Towards Personalized Medicine, Therapeutics and Improved Mechanistic Understanding

Message from the Guest Editors

Advancing research for neuromuscular and neurodegenerative diseases requires a coordinated effort between clinicians, scientists, patients and their families, and other stakeholders. This collaboration drives the collection of samples and the direction of clinical investigation, and combined with recent progress in terms of genetic and genomic analysis has enabled the research community to make real gains towards improvements in patient care. The identification of different groups and subgroups of patients affected by a specific disease pushes the scientific community to move toward personalised/stratified therapeutic strategies. Deciphering the cascade of mechanisms being affected in each subgroup improves our understanding of a given disease and helps us to identify biomarkers and therapeutic strategies. This Special Issue is dedicated to recent research progress in neuromuscular and neurodegenerative diseases, with a focus on biomarkers, clinical indicators, mechanisms explaining or contributing to irreversible cell loss and therapeutic strategies. Up-to-date original research papers, communications and reviews will be considered.

Guest Editors

Dr. Stephanie Duguez

Prof. Dr. Pierre Francois Pradat

Prof. Dr. Julie Dumonceaux

Deadline for manuscript submissions

closed (15 August 2023)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 4.1 Indexed in PubMed



mdpi.com/si/101065

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 4.1 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.4 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2024).